Compare Eli Lilly And Co (LLY) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Northrop Grumman Corporation — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Northrop Grumman Corporation trades at $480.72 (market cap $68.83B). The key difference: Eli Lilly And Co is far larger — about 15.1× Northrop Grumman Corporation's market cap, and Northrop Grumman Corporation pays the higher dividend (2.04%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Northrop Grumman Corporation for 81 Days on average.
| LLY | NOC | |
|---|---|---|
Market Cap | $1.04T | $68.83B |
Volume | 3,064,878 | 1,081,989 |
Sector | Health | Industrials |
52-Week High | $1.28K | $768.02 |
52-Week Low | $799.57 | $473.46 |
Typical Hold Time | 93 Days | 81 Days |
Enterprise Value | $1.09T | $82.81B |
Dividend Yield | 0.59% | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
Northrop Grumman (NOC) trades at $484.48, up 2.33% on the day, but technical indicators signal a bearish trend. The company demonstrates strong fundamentals with consistent earnings beats, a net income margin of 10.48%, and a robust backlog. Recent news highlights a competitive setback with Boeing winning a major Navy contract, though the company maintains solid defense sector positioning.
The outlook is mixed; strong profitability and analyst buy ratings support upside to a $600.62 consensus target, but near-term technical pressure and contract loss risks pose challenges. Revenue growth and dividend stability offer investor appeal, though sector volatility and execution risks require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
